Trials / Recruiting
RecruitingNCT04068597
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- CellCentric Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Detailed description
This includes patients with Peripheral T-cell lymphoma.
Conditions
- Haematological Malignancy
- Acute Myeloid Leukemia
- Non Hodgkin Lymphoma
- Multiple Myeloma
- Higher-risk Myelodysplastic Syndrome
- Peripheral T Cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CCS1477 | Oral capsule |
| DRUG | Pomalidomide | oral capsule |
| DRUG | Dexamethasone | oral tablet |
| DRUG | Azacitidine | Powder suspension for Injection |
| DRUG | Venetoclax | Oral tablet |
| DRUG | Bortezomib | Powder for solution for injection |
| DRUG | Ixazomib | Oral capsule |
| DRUG | Elranatamab | Solution for injection |
| DRUG | Teclistamab | Solution for injection |
| DRUG | Lenalidomide | Oral capsule |
| DRUG | Daratumumab | Solution for injection, concentrate for solution for infusion |
Timeline
- Start date
- 2019-08-09
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
- First posted
- 2019-08-28
- Last updated
- 2025-12-18
Locations
39 sites across 5 countries: United States, France, Spain, Sweden, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04068597. Inclusion in this directory is not an endorsement.